Showing results (601-610 of 2,440) with videos related to

Sort By:
Pageof 244
Clinical and Translational Science|June 21, 2022
The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjectsSejung Hwang, Soyoung Lee, Eunwoo Kim, et al.
Clinical and Translational Science|October 19, 2021
Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjectsYun Kim, Sangwon Lee, Yohan Kim, et al.
Clinical and Translational Science|April 28, 2022
A public-private collaboration model for clinical innovationCraig D Wegner, Bobbie Ann Mount, Christine M Colvis
Clinical and Translational Science|January 12, 2016
Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and EgyptiansI S Hamadeh, M H Shahin, S M Lima, et al.
Clinical and Translational Science|June 20, 2014
Academic medical product development: an emerging alliance of technology transfer organizations and the CTSALynn M Rose, Maaike Everts, Caren Heller, et al.
Clinical and Translational Science|August 7, 2019
Development of an Integrated Platform Using Multidisciplinary Real-World Data to Facilitate Biomarker Discovery for Medical ProductsStefan Dabic, Yasameen Azarbaijani, Tigran Karapetyan, et al.
Clinical and Translational Science|July 13, 2026
Population Pharmacokinetics of Intravenous Infusion of Hydromorphone in Critically Ill Patients Supported by Extracorporeal Membrane OxygenationXuehui Gao, Lu Yao, Fang Zeng, et al.
Clinical and Translational Science|July 8, 2026
Advancing PEGylated Drug Evaluation: A Novel Approach to Pegfilgrastim Pharmacokinetic AssessmentElizaveta Svyatova, Da Shi, Ankit Shah, et al.
Clinical and Translational Science|June 22, 2026
A Phase 1, Open-Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy ParticipantsDavid Cassie, Bob Warnock, Faisal Akhtar, et al.
Clinical and Translational Science|June 19, 2026
Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMATakahiro Handa, Arata Tanaka, Mayumi Shikano, et al.
Pageof 244